PRIME002: Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy.
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2018
At a glance
- Drugs Azacitidine (Primary) ; Carboplatin (Primary) ; Avelumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PRIME002
- 12 Sep 2018 Status changed from not yet recruiting to recruiting.
- 17 Jan 2018 New trial record